135 related articles for article (PubMed ID: 9200950)
1. [The gene therapy for a patient with ADA deficiency; report of the first gene therapy trial in Japan].
Ariga T; Kawamura N; Sakiyama Y
Nihon Rinsho; 1997 Jun; 55(6):1572-9. PubMed ID: 9200950
[TBL] [Abstract][Full Text] [Related]
2. [Gene therapy for adenosine deaminase deficiency].
Sakiyama Y
Hokkaido Igaku Zasshi; 1996 Jan; 71(1):27-32. PubMed ID: 8727372
[TBL] [Abstract][Full Text] [Related]
3. [Study of T cell-directed gene transfer for a patient with ADA deficiency].
Sakiyama Y; Ariga T; Kawamura N
Nihon Rinsho; 1998 Mar; 56(3):696-700. PubMed ID: 9549359
[TBL] [Abstract][Full Text] [Related]
4. In vivo kinetics of transduced cells in peripheral T cell-directed gene therapy: role of CD8+ cells in improved immunological function in an adenosine deaminase (ADA)-SCID patient.
Kawamura N; Ariga T; Ohtsu M; Kobayashi I; Yamada M; Tame A; Furuta H; Okano M; Egashira M; Niikawa N; Kobayashi K; Sakiyama Y
J Immunol; 1999 Aug; 163(4):2256-61. PubMed ID: 10438969
[TBL] [Abstract][Full Text] [Related]
5. Visible integration of the adenosine deaminase (ADA) gene into the recipient genome after gene therapy.
Egashira M; Ariga T; Kawamura N; Miyoshi O; Niikawa N; Sakiyama Y
Am J Med Genet; 1998 Jan; 75(3):314-7. PubMed ID: 9475605
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow gene therapy for adenosine deaminase deficiency.
Kaptein LC; Einerhand MP; Braakman E; Valerio D; van Beusechem VW
Immunodeficiency; 1993; 4(1-4):335-45. PubMed ID: 7909479
[TBL] [Abstract][Full Text] [Related]
7. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
Hershfield MS
Semin Hematol; 1998 Oct; 35(4):291-8. PubMed ID: 9801258
[TBL] [Abstract][Full Text] [Related]
8. [Gene therapy for adenosine deaminase (ADA) deficiency: review of the past, the present and the future].
Ariga T
Nihon Rinsho; 2001 Jan; 59(1):72-5. PubMed ID: 11197865
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow gene transfer in three patients with adenosine deaminase deficiency.
Hoogerbrugge PM; van Beusechem VW; Fischer A; Debree M; le Deist F; Perignon JL; Morgan G; Gaspar B; Fairbanks LD; Skeoch CH; Moseley A; Harvey M; Levinsky RJ; Valerio D
Gene Ther; 1996 Feb; 3(2):179-83. PubMed ID: 8867866
[TBL] [Abstract][Full Text] [Related]
10. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
[TBL] [Abstract][Full Text] [Related]
11. [Gene therapy for adenosine deaminase deficiency].
Sakiyama Y; Ariga T; Ohtsu M
Nihon Rinsho; 2005 Mar; 63(3):448-52. PubMed ID: 15773344
[TBL] [Abstract][Full Text] [Related]
12. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency.
Onodera M; Ariga T; Kawamura N; Kobayashi I; Ohtsu M; Yamada M; Tame A; Furuta H; Okano M; Matsumoto S; Kotani H; McGarrity GJ; Blaese RM; Sakiyama Y
Blood; 1998 Jan; 91(1):30-6. PubMed ID: 9414266
[TBL] [Abstract][Full Text] [Related]
13. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency.
Carbonaro DA; Jin X; Petersen D; Wang X; Dorey F; Kil KS; Aldrich M; Blackburn MR; Kellems RE; Kohn DB
Mol Ther; 2006 Jun; 13(6):1110-20. PubMed ID: 16651028
[TBL] [Abstract][Full Text] [Related]
14. Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency.
Ramsey WJ; Mullen CA; Blaese RM
Leukemia; 1995 Oct; 9 Suppl 1():S70. PubMed ID: 7475319
[TBL] [Abstract][Full Text] [Related]
15. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
Taupin P
IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM
Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for hematopoietic and immune disorders.
Kohn DB
Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S55-8. PubMed ID: 8971410
[TBL] [Abstract][Full Text] [Related]
18. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of the induced T cells in a ADA-defective case 4 years after gene induction targeted at the peripheral T cells and a simulation study on gene re-induction].
Ichimura R
Hokkaido Igaku Zasshi; 2004 Nov; 79(6):647-57. PubMed ID: 15675295
[No Abstract] [Full Text] [Related]
20. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency.
Blaese RM
Pediatr Res; 1993 Jan; 33(1 Suppl):S49-53; discussion S53-5. PubMed ID: 8433875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]